Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma
Ratiometric delivery of combination chemotherapy can achieve therapeutic efficacy based on synergistic interactions between drugs. It is critical to design such combinations with drugs that complement each other and reduce cancer growth through multiple mechanisms. Using hyaluronic acid (HA) as a ca...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/2/466 |
| _version_ | 1797477175885037568 |
|---|---|
| author | Vinu Krishnan Vimisha Dharamdasani Shirin Bakre Ved Dhole Debra Wu Bogdan Budnik Samir Mitragotri |
| author_facet | Vinu Krishnan Vimisha Dharamdasani Shirin Bakre Ved Dhole Debra Wu Bogdan Budnik Samir Mitragotri |
| author_sort | Vinu Krishnan |
| collection | DOAJ |
| description | Ratiometric delivery of combination chemotherapy can achieve therapeutic efficacy based on synergistic interactions between drugs. It is critical to design such combinations with drugs that complement each other and reduce cancer growth through multiple mechanisms. Using hyaluronic acid (HA) as a carrier, two chemotherapeutic agents—doxorubicin (DOX) and camptothecin (CPT)—were incorporated and tested for their synergistic potency against a broad panel of blood-cancer cell lines. The pair also demonstrated the ability to achieve immunogenic cell death by increasing the surface exposure levels of Calreticulin, thereby highlighting its ability to induce apoptosis via an alternate pathway. Global proteomic profiling of cancer cells treated with HA–DOX–CPT identified pathways that could potentially predict patient sensitivity to HA–DOX–CPT. This lays the foundation for further exploration of integrating drug delivery and proteomics in personalized immunogenic chemotherapy. |
| first_indexed | 2024-03-09T21:13:55Z |
| format | Article |
| id | doaj.art-5be87aba328b4b5fb1c169fac1623352 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T21:13:55Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-5be87aba328b4b5fb1c169fac16233522023-11-23T21:39:44ZengMDPI AGPharmaceutics1999-49232022-02-0114246610.3390/pharmaceutics14020466Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell LymphomaVinu Krishnan0Vimisha Dharamdasani1Shirin Bakre2Ved Dhole3Debra Wu4Bogdan Budnik5Samir Mitragotri6School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USASchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USASchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USASchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USASchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USAMass Spectrometry Proteomics and Research Laboratory, FAS Division of Science, Harvard University, Cambridge, MA 02138, USASchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USARatiometric delivery of combination chemotherapy can achieve therapeutic efficacy based on synergistic interactions between drugs. It is critical to design such combinations with drugs that complement each other and reduce cancer growth through multiple mechanisms. Using hyaluronic acid (HA) as a carrier, two chemotherapeutic agents—doxorubicin (DOX) and camptothecin (CPT)—were incorporated and tested for their synergistic potency against a broad panel of blood-cancer cell lines. The pair also demonstrated the ability to achieve immunogenic cell death by increasing the surface exposure levels of Calreticulin, thereby highlighting its ability to induce apoptosis via an alternate pathway. Global proteomic profiling of cancer cells treated with HA–DOX–CPT identified pathways that could potentially predict patient sensitivity to HA–DOX–CPT. This lays the foundation for further exploration of integrating drug delivery and proteomics in personalized immunogenic chemotherapy.https://www.mdpi.com/1999-4923/14/2/466hyaluronic acid nanoparticlesleukemialymphomadrug delivery |
| spellingShingle | Vinu Krishnan Vimisha Dharamdasani Shirin Bakre Ved Dhole Debra Wu Bogdan Budnik Samir Mitragotri Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma Pharmaceutics hyaluronic acid nanoparticles leukemia lymphoma drug delivery |
| title | Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma |
| title_full | Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma |
| title_fullStr | Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma |
| title_full_unstemmed | Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma |
| title_short | Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma |
| title_sort | hyaluronic acid nanoparticles for immunogenic chemotherapy of leukemia and t cell lymphoma |
| topic | hyaluronic acid nanoparticles leukemia lymphoma drug delivery |
| url | https://www.mdpi.com/1999-4923/14/2/466 |
| work_keys_str_mv | AT vinukrishnan hyaluronicacidnanoparticlesforimmunogenicchemotherapyofleukemiaandtcelllymphoma AT vimishadharamdasani hyaluronicacidnanoparticlesforimmunogenicchemotherapyofleukemiaandtcelllymphoma AT shirinbakre hyaluronicacidnanoparticlesforimmunogenicchemotherapyofleukemiaandtcelllymphoma AT veddhole hyaluronicacidnanoparticlesforimmunogenicchemotherapyofleukemiaandtcelllymphoma AT debrawu hyaluronicacidnanoparticlesforimmunogenicchemotherapyofleukemiaandtcelllymphoma AT bogdanbudnik hyaluronicacidnanoparticlesforimmunogenicchemotherapyofleukemiaandtcelllymphoma AT samirmitragotri hyaluronicacidnanoparticlesforimmunogenicchemotherapyofleukemiaandtcelllymphoma |